European Immunization Week 2018- Statement of Guido Rasi, Executive Director, European Medicines Agency

Posted on: 26/04/2018 - 13:27

Vaccines matter for each of us: yearly, they prevent 2.7 million people from contracting measles, one million from getting whooping cough and two million babies from getting tetanus. They eradicated smallpox. They stopped polio, a dreadful disease affecting millions of children, in almost all... more

Field of Interest: European Union Medical News
Type: News Feed

First European Medicines Agency (EMA) and Active Pharmaceutical Ingredients Committee (APIC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 September 2026, 15:30 (CEST) to 2 September 2026, 17:30 (CEST)

Submitted by Anonymous (not verified) on 23 September 2026 - 15:40

First European Medicines Agency (EMA) and Active Pharmaceutical Ingredients Committee (APIC) bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, from 2 September 2026, 15:30 (CEST) to 2 September 2026, 17:30 (CEST)

Regulatory perspectives on herbal medicinal / botanical drug product development: Joint FDA / EMA workshop, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 September 2026, 10:00 (CEST) to 25 September 2026, 13:00 (CEST)

Submitted by Anonymous (not verified) on 23 September 2026 - 15:30

Regulatory perspectives on herbal medicinal / botanical drug product development: Joint FDA / EMA workshop, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 25 September 2026, 10:00 (CEST) to 25 September 2026, 13:00 (CEST)

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 7, Status: Authorised

Submitted by Anonymous (not verified) on 23 September 2026 - 15:26

Human medicines European public assessment report (EPAR): Otulfi, ustekinumab, Date of authorisation: 25/09/2024, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Date of authorisation: 18/12/2020, Revision: 20, Status: Authorised

Submitted by Anonymous (not verified) on 23 September 2026 - 14:05

Human medicines European public assessment report (EPAR): Fintepla, fenfluramine, Date of authorisation: 18/12/2020, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Dimethyl fumarate Accord, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 4, Status: Authorised

Submitted by Anonymous (not verified) on 23 September 2026 - 13:55

Human medicines European public assessment report (EPAR): Dimethyl fumarate Accord, dimethyl fumarate, Date of authorisation: 22/04/2024, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Onerji, levodopa,carbidopa, Date of authorisation: 27/04/2026, Revision: 1, Status: Authorised

Submitted by Anonymous (not verified) on 23 September 2026 - 13:50

Human medicines European public assessment report (EPAR): Onerji, levodopa,carbidopa, Date of authorisation: 27/04/2026, Revision: 1, Status: Authorised

List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment

Submitted by Anonymous (not verified) on 23 September 2026 - 11:00

List of clinical evaluation consultation procedure (CECP) opinions issued for medical devices awaiting finalisation of conformity assessment

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More